TE-64562 inhibits tumor growth in MDA-MB-231 xenograft tumors and increases survival with no observed toxicity.

<p>(<b>A–C</b>) MDA-MB-231 xenograft tumors were grown in the subcutaneous flank region of nude mice which were treated bi-weekly with the TE-64562 peptide (40 mg/kg; 7 µmol/kg), Tat-peptide (20 mg/kg; 7 µmol/kg) or vehicle (saline), intraperitoneally. (<b>A</b>) The mean tumor size (± standard error of the mean) is plotted over time. The asterisks (*P≤0.0325) indicate that the mean size of the TE-64562 treated tumors is statistically different from the saline- and Tat-treated tumor sizes at that time point. (<b>B</b>) The number of mice within endpoints, as defined by tumor size cutoff, tumor ulceration and body conditioning scoring, at each time point are plotted as a Kaplan and Meier survival curve. (<b>B</b>, inset) The median survival, the number of days at which the fraction of mice within endpoints is equal to 50%, is plotted for each treatment group. The survival curves for the Tat and Saline groups were compared to the survival curve for the TE-64562 group and the P value was derived using the log-rank (Mantel-Cox) test. The asterisks (*) designate a significant difference with the indicated P values. (<b>C</b>) The mean body weight (± standard error of the mean) for each treatment group is plotted over time. (<b>D</b>) After 35 days of dosing, organs were collected and fixed. Representative H&E stained sections from liver, kidney and spleen are shown for each treatment group. Results are representative of two independent studies. Also see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0049702#pone.0049702.s004" target="_blank">Figure S4</a>.</p>